ENDPOINTS NEWS23 分钟
J&J’s Ry­bre­vant gets CHMP back­ing weeks af­ter FDA re­jec­tion
Johnson & Johnson’s subcutaneous form of Rybrevant has been recommended for approval by the European Medicines Agency’s human ...
ENDPOINTS NEWS32 分钟
Pfiz­er says new col­orec­tal can­cer da­ta could sup­port full ap­proval of Braftovi
Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and ...